Theralase Technologies Inc.  

(Public, CVE:TLT)   Watch this stock  
Find more results for TLT
+0.015 (4.84%)
Apr 17 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.31 - 0.32
52 week 0.15 - 0.56
Open 0.31
Vol / Avg. 243,567.00/381,138.00
Mkt cap 21.62M
P/E     -
Div/yield     -
EPS -0.02
Shares 66.53M
Beta 0.78
Inst. own     -
Apr 28, 2014
Q4 2013 Theralase Technologies Inc Earnings Release (Estimated) Add to calendar

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -59.35% -83.85%
Operating margin -57.86% -82.75%
EBITD margin - -80.07%
Return on average assets -62.28% -120.28%
Return on average equity - -773.29%
CDP Score - -


1945 Queen Street East
+1-416-6995273 (Phone)
+1-416-6995250 (Fax)

Website links


Theralase Technologies Inc. designs, develops, manufactures and markets patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: first, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; second, wound care and healing (including non-healing fractures and bone fracture regeneration); and third, research and development into combining patented photodynamic compounds with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses. It focuses on the production, marketing and distribution of the TLC-1000 and TLC-2000 Theralase Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Officers and directors

S. Donald Moore Chairman of the Board
Roger Dumoulin-White President, Chief Executive Officer, Director
Kristina Hachey Chief Financial Officer
Matthew Perraton Director
Guy J. Anderson Independent Director
Randy Bruder Independent Director